Cosmo First
Cosmo First Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #16 of 100 in Industrial Products
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 3 strong
The short version
Overall business revenue expected to grow by 20% in the current year (FY27). Overall company revenue expected to grow by at least 20% in the current year (FY27). - New businesses projected to grow at a rapid pace of around 60% this year. - Specialty chemical business expected to grow ~50% with 25% EBITDA margins. - Plastech business turned profitable in Q1 FY27; targeting double-digit profitability by year-end and aiming for 15%-20%+ ROCE as it scales to Rs.
From Cosmo First's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Overall business revenue expected to grow by 20% in the current year (FY27).
- New businesses projected to grow at 60% in the current year.
- Specialty film sales aimed to increase to 35%-40% gross margins with scaling revenue, though this will take time.
- Cosmo Consumer business expected to grow rapidly, with over 3x growth projected this year in the domestic market.
- Zigly is scaling with a current run rate of ~Rs. 100 crores annualized and targets breakeven at Rs. 250 crores revenue in next couple of years.
- Plastech business projected to grow from Rs. 100 crores last year to Rs. 150-160 crores this year and ~Rs. 200+ crores next year, with improving margins and ROCE.
2 more points from Cosmo First's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Cosmo First said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Minimal Capex planned over the next two years to contain significant capital expenditure.
- Recent investments have created substantial headroom to scale specialty films sales to close to 90% without major new Capex.
- On the Plastech side, capacity to be expanded by 50% with minimal Capex, enabling revenue growth from Rs. 100 crores to Rs. 200-250 crores by next year.
- Incremental Capex is directed primarily at specialty assets, including development and launch of new specialty films and products.
- Existing specialty business has sufficient capacity; new capacity added recently supports growth targets.
2 more points from Cosmo First's call on capex
Create a free account to keep reading this call
Top-ranked in Industrial Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cosmo First said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Cosmo First's call on order book
Create a free account to keep reading this call
Cosmo First — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.0K Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cosmo First's management said in earlier quarters
Others in Industrial Products this season
- Expo Engineering (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹13.75 crore, down from ₹17.85 crore in Q1 FY26 (approx. Key investor presentation takeaways from Expo Engineering and Projects
- Sh. Bajrang All. (Q1 FY27)
Shareholding pattern as of 30 June 2026: Promoter 63.97%, Public 36.03%. Key investor presentation takeaways from Shri Bajrang Alliance Ltd's Q1 FY27 investor p
- Bedmutha Indus. (Q1 FY27)
Revenue from Operations for the year ended March 31, 2026: Rs 1466.74 crores versus Rs 1049.33 crores for March 31, 2025, indicating a significant year-on-year…
- Horizon Reclaim (Q1 FY27)
Reported Revenue (₹ Cr): . Key investor presentation takeaways from Horizon Reclaim (India) Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Potential multibaggers · Q2 FY27
Potential multibaggers in Industrial Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cosmo First and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cosmo First Q1 FY27 results?
Overall business revenue expected to grow by 20% in the current year (FY27). Overall company revenue expected to grow by at least 20% in the current year (FY27). - New businesses projected to grow at a rapid pace of around 60% this year. - Specialty chemical business expected to grow ~50% with 25% EBITDA margins. - Plastech business turned profitable in Q1 FY27; targeting double-digit profitability by year-end and aiming for 15%-20%+ ROCE as it scales to Rs.
What is Cosmo First share price analysis?
Cosmo First currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 14.1 with a market cap of ₹2,423 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cosmo First planning capital expenditure?
Minimal Capex planned over the next two years to contain significant capital expenditure. - Recent investments have created substantial headroom to scale specialty films sales to close to 90% without major new Capex. - On the Plastech side, capacity to be expanded by 50% with minimal Capex, enabling revenue growth from Rs.
Keep Cosmo First on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
